Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SQZ-eAPC-HPV + pembrolizumab
- Development stage
- Unknown
- Lead developer
- SQZ Biotechnologies
- Modality
- Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (SQZ-eAPC-HPV), Intravenous (pembrolizumab)
01
Overview
SQZ-eAPC-HPV + pembrolizumab is a combination of a novel mRNA-engineered autologous cell therapy, derived from peripheral blood mononuclear cells (PBMCs) and engineered to target the HPV16 E6 and E7 oncoproteins, with the immune checkpoint inhibitor pembrolizumab. SQZ-eAPC-HPV utilizes the Enhanced Antigen Presenting Cell (eAPC) platform, delivering multiple mRNAs encoding tumor antigens, a costimulatory molecule (CD86), and membrane-bound cytokines (IL-2 and IL-12) into four types of immune cells (monocytes, T cells, B cells, NK cells). Its mechanism is to stimulate antigen-specific T cell responses against HPV16+ tumor cells. Pembrolizumab acts by blocking programmed death-1 (PD-1) receptor, preventing immune suppression. This combination aims to enhance immune recognition and killing of HPV16+ solid tumors, and is being evaluated in a Phase 1/2 clinical trial (COMMANDER-001) for patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors, including head and neck, cervical, anal, vulvar, or penile cancers[1][3][4][5][6][7].
- Brand names
- SQZ-eAPC-HPV + pembrolizumab
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)IL-12R (Interleukin-12 receptor)PDCD1 (Programmed cell death protein 1 receptor)CD28 (Cluster of Differentiation 28)HPV16 E7 (Human papillomavirus 16 E7 protein)HPV16 E6 oncoprotein
Beyond the preview
Go deeper on SQZ-eAPC-HPV + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SQZ-eAPC-HPV + pembrolizumab.